Quanti cation of Immunoglobulin G against Trypanosoma cruzi in Individuals with Chronic Chagas Disease Treated with Nifurtimox and Evaluated in Prolonged Follow-Up
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
In the indeterminate chronic period of Chagas disease (ChD) the treatment has not been conclusive, because the serological negativization requires many years. This study aims to evaluate the efficacy of nifurtimox (NF) in the treat- ment of chronic ChD in prolonged follow-up by serological techniques of indirect immunofluorescence assay (IFA) and enzyme-linked immunosorbent assay (ELISA) IgG comparing 2 groups of patients, treated and non treated. Mann-Whit- ney test was performed for ELISA and IFA, with significant difference between the groups (P < 0.05). IgG levels were lower in individuals treated compared with untreated patients, indicating chemotherapeutic efficacy in prolonged follow-up.
Abstract
In the indeterminate chronic period of Chagas disease (ChD) the treatment has not been conclusive, because the serological negativization requires many years. This study aims to evaluate the efficacy of nifurtimox (NF) in the treat- ment of chronic ChD in prolonged follow-up by serological techniques of indirect immunofluorescence assay (IFA) and enzyme-linked immunosorbent assay (ELISA) IgG comparing 2 groups of patients, treated and non treated. Mann-Whit- ney test was performed for ELISA and IFA, with significant difference between the groups (P < 0.05). IgG levels were lower in individuals treated compared with untreated patients, indicating chemotherapeutic efficacy in prolonged follow-up.
참고문헌 (14)
- Toso A, "Transmisión de la enfermedad de Chagas por vía oral", Rev Méd Chile, 139, pp.258~266 (2011)[DOI]
- Rassi A Jr, "American Trypanosomiasis(Chagas disease)", Infect Dis Clin North Am, 26, pp.275~291 (2012)
- Cabello C, "Zoonosis con reservorios silvestres : amenazas a la salud pública y a la economía", Rev Méd Chile, 136, pp.385~393 (2008)[DOI]
- World Health Organization, "Chagas disease in Latin America: an epidemiological update based on 2010 estimates", Wkly Epidemiol Rec, 90, pp.33~44 (2015)
- Pérez-Molina JA, "Chagas disease", Lancet, 391, pp.82~94 (2018)
- Apt W, "Estado actual en el tratamiento de la enfermedad de Chagas", Rev Méd Chile, 139, pp.247~257 (2011)[DOI]
- Bern C, "Antitrypanosomal therapy for chronic Chagas’ disease", N Engl J Med, 364, pp.2527~2534 (2011)
- Sguassero Y, "Course of chronic Trypanosoma cruzi infection after treatment based on parasitological and serological test : a systematic review of follow-up studies", PLoS One, 10, pp.e0139363~ (2015)
- Ministerio de Salud, "Guía de diagnóstico, tratamiento y prevención de la enfermedad de Chagas. Guías Clínicas 2011", ~ (2011)
- Flores-Chávez M, "Comparación de técnicas serológicas convencionales y no convencionales para el diagnóstico de la enfermedad de Chagas importada en España", Enferm Infecc Microbiol Clin, 28, pp.284~293 (2010)
- Astorga B, "Determinación de la reacción de Inmunofluorescencia indirecta para la enfermedad de Chagas en Chile", Parasitología al Dia, 12, pp.132~135 (1998)[DOI]
- Luquetti A, "Perspectiva del uso de la serología (Ag naturales y otros) en la evaluación de la eficacia del tratamiento etiológico", 2nd Simposio Internacional de Enfermedad de Chagas 2002 (2002)
- Rassi A, "Specific treatment for Trypanosoma cruzi : lack of efficacy of allopurinol in the human chronic phase of Chagas disease", Am J Trop Med Hyg, 76, pp.58~61 (2007)
- Luquetti A, "American Trypanosomiasis Chagas Disease", pp.687~730 (2017), Elsevier